Clinical Trial Detail

NCT ID NCT03496662
Title BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

pancreatic ductal adenocarcinoma

Therapies

Nivolumab

BMS-813160 + Gemcitabine + Nab-paclitaxel

Gemcitabine + Nab-paclitaxel

BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab

Age Groups: adult senior

No variant requirements are available.